221 related articles for article (PubMed ID: 35579105)
1. Development of a potent small-molecule degrader against oncogenic BRAF
Ohoka N; Suzuki M; Uchida T; Tsukumo Y; Yoshida M; Inoue T; Ohki H; Naito M
Cancer Sci; 2022 Aug; 113(8):2828-2838. PubMed ID: 35579105
[TBL] [Abstract][Full Text] [Related]
2. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
3. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
4. PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.
Tutuka CSA; Andrews MC; Mariadason JM; Ioannidis P; Hudson C; Cebon J; Behren A
Mol Cancer; 2017 Jun; 16(1):112. PubMed ID: 28659148
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
6. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
7. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
[TBL] [Abstract][Full Text] [Related]
8. Mechanism and inhibition of BRAF kinase.
Gunderwala A; Cope N; Wang Z
Curr Opin Chem Biol; 2022 Dec; 71():102205. PubMed ID: 36067564
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Selective Small Molecule Degraders of BRAF-V600E.
Han XR; Chen L; Wei Y; Yu W; Chen Y; Zhang C; Jiao B; Shi T; Sun L; Zhang C; Xu Y; Lee MR; Luo Y; Plewe MB; Wang J
J Med Chem; 2020 Apr; 63(8):4069-4080. PubMed ID: 32223235
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
Basile KJ; Le K; Hartsough EJ; Aplin AE
Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
[TBL] [Abstract][Full Text] [Related]
11. Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF
Grasso M; Estrada MA; Ventocilla C; Samanta M; Maksimoska J; Villanueva J; Winkler JD; Marmorstein R
ACS Chem Biol; 2016 Oct; 11(10):2876-2888. PubMed ID: 27571413
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF
Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC
Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716
[TBL] [Abstract][Full Text] [Related]
13. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
[TBL] [Abstract][Full Text] [Related]
14. Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAF
Marini E; Marino M; Gionfriddo G; Maione F; Pandini M; Oddo D; Giorgis M; Rolando B; Blua F; Gastaldi S; Marchiò S; Kovachka S; Spyrakis F; Gianquinto E; Di Nicolantonio F; Bertinaria M
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500607
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
16. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
17. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
18. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization of a PROTAC directed against BRAF mutant V600E.
Posternak G; Tang X; Maisonneuve P; Jin T; Lavoie H; Daou S; Orlicky S; Goullet de Rugy T; Caldwell L; Chan K; Aman A; Prakesch M; Poda G; Mader P; Wong C; Maier S; Kitaygorodsky J; Larsen B; Colwill K; Yin Z; Ceccarelli DF; Batey RA; Taipale M; Kurinov I; Uehling D; Wrana J; Durocher D; Gingras AC; Al-Awar R; Therrien M; Sicheri F
Nat Chem Biol; 2020 Nov; 16(11):1170-1178. PubMed ID: 32778845
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
